Literature DB >> 3005210

Mechanism of the cytotoxic effect of tumor necrosis factor.

Y Niitsu, N Watanabe, H Sone, H Neda, N Yamauchi, I Urushizaki.   

Abstract

The mechanism of murine tumor necrosis factor (TNF) cytotoxicity against tumor cell lines (L929, HeLa, K562) was investigated. Electron microscopic observation revealed that most of the organellas of L929 cells incubated with partially purified murine TNF underwent almost complete lysis with no drastic disruption of the cytoplasmic membrane, while injection of the TNF into the cytoplasm or nuclei of L929 cells caused no apparent morphological change or growth inhibition. Preincubation of the TNF with tumor cells (L929, HeLa, K562) resulted in a decrease in cytotoxic activity which was proportional to their susceptibility to TNF, thus indicating their absorption of TNF. The susceptibility of L929 tumor cells to TNF was apparently suppressed by treatment with proteases, suggesting the existence of protease-sensitive recognition sites for TNF on the tumor cell.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3005210

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  12 in total

1.  Synergistic cytotoxicity of human recombinant tumour necrosis factor alpha combined with microtubule effectors.

Authors:  J Baumgart; B Schlott; J Suehnel; W Vater; W Schulze; D Behnke
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

2.  Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo.

Authors:  M Fràter-Schröder; W Risau; R Hallmann; P Gautschi; P Böhlen
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

3.  Signalling pathway of tumor necrosis factor in normal and tumor cells.

Authors:  N Watanabe; H Neda; Y Ohtusuka; H Sone; N Yamauchi; M Maeda; H Kuriyama; Y Niitsu
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

4.  Structural changes of tumor necrosis factor alpha associated with membrane insertion and channel formation.

Authors:  R L Baldwin; M L Stolowitz; L Hood; B J Wisnieski
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-06       Impact factor: 11.205

5.  Spontaneous production of bone-resorbing lymphokines by B cells in patients with systemic lupus erythematosus.

Authors:  Y Tanaka; K Watanabe; M Suzuki; K Saito; S Oda; H Suzuki; S Eto; U Yamashita
Journal:  J Clin Immunol       Date:  1989-09       Impact factor: 8.317

6.  An antimelanoma immunotoxin containing recombinant human tumor necrosis factor: tissue disposition, pharmacokinetic, and therapeutic studies in xenograft models.

Authors:  M G Rosenblum; L Cheung; K Mujoo; J L Murray
Journal:  Cancer Immunol Immunother       Date:  1995-05       Impact factor: 6.968

7.  Comparison of the intoxication pathways of tumor necrosis factor and diphtheria toxin.

Authors:  M P Chang; B J Wisnieski
Journal:  Infect Immun       Date:  1990-08       Impact factor: 3.441

8.  Antitumor effects of recombinant human tumor necrosis factor against human tumor xenografts transplanted into nude mice.

Authors:  Y Nosoh; T Toge; M Nishiyama; M Yamaguchi; N Hirabayashi; M Niimoto; T Hattori
Journal:  Jpn J Surg       Date:  1987-01

9.  Enhancement of lysosomal enzyme activity by recombinant human tumor necrosis factor and its role in tumor cell killing in vitro.

Authors:  N Watanabe; N Yamauchi; H Neda; M Maeda; Y Tsuji; T Okamoto; S Akiyama; H Sasaki; N Tsuji; Y Niitsu
Journal:  Jpn J Cancer Res       Date:  1992-06

10.  Lysosome labilizers potentiate the antitumor effects of tumor necrosis factor-alpha.

Authors:  T Masegi; A Kato; K Kitai; M Fukuoka; K Soma; Y Ichikawa; S Nakamura; N Watanabe; Y Niitsu
Journal:  Jpn J Cancer Res       Date:  1993-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.